Dr. Nakadar's Office
Sterling Heights, Michigan, 48310, United States
NCT Number: NCT04088929
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 2
Sterling Heights, Michigan, 48310, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
Time frame: Three Weeks
To evaluate the safety and efficacy of Pure Green CBD sublingual tablets for the treatment of chronic diabetic neuropathic pain patients by evaluating their daily pain scale score reported as 0-10 where 0 is no pain and 10 is the worst pain possible as self-reported with every dose taken by the patient in the smart phone app. The objective is to reduce the patients average daily pain scale score to less than 5.
Time frame: Three Weeks
To evaluate the impact of Pure Green CBD sublingual tablets on the quality of life of diabetic neuropathy patients measured by World Health Organization's quality of life questionnaire, . The objective is to examine quality of life metrics: overall quality of life and general health, physical health, psychological, social, and environment as measured on a 1-5 scale before and after the study.
Time frame: Three weeks
The Pittsburgh Sleep Quality Index will be used to compare pre and post Pure Green CBD tablet study on sleep changes. Patients will be asked questions before beginning the study and after completion.
Time frame: Three Weeks
The Hamilton Anxiety rating scale questionnaire will be administered before the study begins and after completion to examine the impact of Pure Green CBD tablets on anxiety in diabetic neuropathy pain patients. The scale of 0-4 will be used where 0 is no anxiety present and 4 is very severe anxiety.
Time frame: Three Weeks
To explore the impact of sublingual administration on patient compliance by evaluating the number of tablets taken per day as entered by the patients into the smart phone app.
Pure Green
Industry
A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06292962
Diabetes Complications, Diabetes Mellitus
Lahore, Pakistan
View Trial DetailsNCT00082316
Blood-Borne Infections, Communicable Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT05984771
Diabetes Complications, Diabetes Mellitus
Thessaloniki, Greece
View Trial DetailsNCT05322746
Diabetes Complications, Diabetes Mellitus
Toba Tek Singh, Punjab Province, Pakistan
View Trial Details